Kamil Kuca Selected Research

Organophosphate Poisoning

7/2020	Safety and Efficacy of New Oximes to Reverse Low Dose Diethyl-Paraoxon-Induced Ventilatory Effects in Rats.
1/2019	Oxime K203: a drug candidate for the treatment of tabun intoxication.
12/2018	Pyridinium Oximes with Ortho-Positioned Chlorine Moiety Exhibit Improved Physicochemical Properties and Efficient Reactivation of Human Acetylcholinesterase Inhibited by Several Nerve Agents.
1/2016	Development and validation of a FIA/UV-vis method for pK(a) determination of oxime based acetylcholinesterase reactivators.
10/2014	Assessment of antidotal efficacy of cholinesterase reactivators against paraoxon: In vitro reactivation kinetics and physicochemical properties.
4/2014	In vivo evaluation of cholinesterase activity, oxidative stress markers, cyto- and genotoxicity of K048 oxime–a promising antidote against organophosphate poisoning.
12/2012	The progress in the cholinesterase quantification methods.
4/2011	The preparation, in vitro screening and molecular docking of symmetrical bisquaternary cholinesterase inhibitors containing a but-(2E)-en-1,4-diyl connecting linkage.
1/2011	Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.
9/2010	Characterization of the anticholinergic properties of obidoxime; functional examinations of the rat atria and the urinary bladder.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kamil Kuca Research Topics

Disease

78	Poisoning 02/2022 - 01/2004
49	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 01/2004
28	Neoplasms (Cancer) 06/2022 - 11/2013
14	Organophosphate Poisoning 07/2020 - 08/2006
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2015
7	Infections 03/2021 - 01/2010
6	COVID-19 01/2022 - 01/2021
6	Dementia (Dementias) 01/2019 - 01/2016
5	Hypoxia (Hypoxemia) 01/2022 - 01/2020
5	Body Weight (Weight, Body) 10/2021 - 01/2013
5	Myasthenia Gravis 02/2016 - 11/2009
4	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 01/2017
4	Cognitive Dysfunction 01/2019 - 01/2017
3	Inflammation (Inflammations) 01/2022 - 01/2017
3	Vomiting 01/2021 - 01/2020
3	Wounds and Injuries (Trauma) 01/2021 - 04/2019
3	Nervous System Diseases (Neurological Disorders) 04/2020 - 01/2015
3	Breast Neoplasms (Breast Cancer) 01/2020 - 12/2017
3	Pain (Aches) 06/2016 - 08/2007
3	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2016 - 01/2014
2	Amyloid Plaque 01/2022 - 01/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 05/2021 - 11/2020
2	Amnesia (Dissociative Amnesia) 01/2021 - 04/2019
2	Schizophrenia (Dementia Praecox) 01/2021 - 01/2015
2	Mental Disorders (Mental Disorder) 01/2021 - 01/2019
2	Heart Failure 10/2020 - 09/2008
2	Epilepsy (Aura) 08/2020 - 01/2015
2	Parkinson Disease (Parkinson's Disease) 03/2020 - 01/2016

Drug/Important Bio-Agent (IBA)

50	OximesIBA 07/2020 - 01/2004
30	AcetylcholinesteraseIBA 01/2021 - 11/2005
30	tabunIBA 01/2019 - 12/2005
19	Nerve AgentsIBA 01/2019 - 11/2005
19	asoxime chloride (H16)IBA 01/2018 - 01/2004
17	Obidoxime Chloride (Obidoxime)IBA 09/2018 - 01/2004
16	Atropine FDA LinkGeneric 07/2020 - 01/2004
13	Tacrine (Cognex)FDA Link 01/2021 - 05/2008
13	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2020 - 03/2010
12	Pharmaceutical PreparationsIBA 01/2022 - 12/2005
12	EnzymesIBA 01/2021 - 01/2004
9	Trimedoxime (Trimedoxime Bromide)IBA 01/2013 - 01/2004
9	cyclohexyl methylphosphonofluoridate (cyclosarin)IBA 06/2009 - 11/2005
8	MycotoxinsIBA 02/2022 - 01/2007
8	Cholinergic Agents (Cholinergics)IBA 01/2020 - 01/2004
8	AntidotesIBA 12/2018 - 04/2008
7	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2015
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2014
6	Biological ProductsIBA 11/2019 - 09/2008
6	OrganophosphatesIBA 01/2018 - 01/2004
6	pralidoxime (Protopam Chloride)FDA Link 12/2011 - 11/2005
5	LigandsIBA 01/2021 - 01/2016
5	T-2 Toxin (T 2 Toxin)IBA 01/2021 - 12/2017
5	Amyloid beta-PeptidesIBA 03/2020 - 08/2012
5	SomanIBA 10/2010 - 02/2006
4	AntioxidantsIBA 05/2022 - 12/2011
4	Antiviral Agents (Antivirals)IBA 10/2021 - 01/2016
4	deoxynivalenolIBA 01/2021 - 01/2020
4	benzothiazoleIBA 01/2021 - 01/2015
4	Therapeutic UsesIBA 01/2019 - 05/2007
4	Cholinesterases (Cholinesterase)IBA 01/2017 - 08/2007
4	Phosphotransferases (Kinase)IBA 01/2016 - 01/2014
4	Cholinergic Antagonists (Anticholinergics)IBA 10/2008 - 11/2005
3	JNK Mitogen-Activated Protein KinasesIBA 01/2022 - 11/2019
3	CytokinesIBA 01/2022 - 08/2018
3	VaccinesIBA 01/2022 - 01/2017
3	Biomarkers (Surrogate Marker)IBA 11/2021 - 01/2019
3	GoldIBA 01/2021 - 10/2016
3	TrichothecenesIBA 01/2021 - 12/2017
3	Oxidoreductases (Dehydrogenase)IBA 03/2020 - 01/2017
3	trichotheceneIBA 01/2020 - 12/2017
3	diacetoxyscirpenolIBA 01/2020 - 12/2017
3	SaltsIBA 12/2019 - 01/2013
3	Memantine (Namenda)FDA Link 01/2019 - 06/2014
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2019 - 01/2015
3	Diazepam (Valium)FDA LinkGeneric 09/2018 - 01/2011
3	SarinIBA 01/2018 - 07/2005
3	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 01/2014
3	Malathion (Karbofos)FDA LinkGeneric 12/2011 - 01/2008
3	CarbamatesIBA 01/2011 - 01/2004
3	Paraoxon (E600)IBA 09/2010 - 11/2007
3	Acetylcholine (Acetylcholine Chloride)FDA Link 03/2010 - 11/2005
2	Antihypertensive Agents (Antihypertensives)IBA 05/2022 - 04/2020
2	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2019
2	Free RadicalsIBA 05/2021 - 11/2020
2	quinolineIBA 01/2021 - 08/2019
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2019
2	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 01/2020
2	Granisetron (Kytril)FDA LinkGeneric 01/2021 - 01/2020
2	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2021 - 01/2020
2	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 01/2019
2	OxidesIBA 01/2021 - 01/2021
2	CopperIBA 01/2021 - 01/2016
2	neuropeptide Y2 receptorIBA 01/2021 - 01/2020
2	Scopolamine (Hyoscine)FDA Link 01/2021 - 04/2019
2	Antidepressive Agents (Antidepressants)IBA 04/2020 - 01/2019
2	Anticonvulsants (Antiepileptic Drugs)IBA 04/2020 - 01/2011
2	InsecticidesIBA 01/2020 - 06/2009
2	Alcohol Dehydrogenase (Alcohol Dehydrogenase (NAD+))IBA 07/2019 - 01/2017

Therapy/Procedure

31	Therapeutics 03/2021 - 02/2006
3	Drug Therapy (Chemotherapy) 11/2021 - 01/2019
2	Immunotherapy 01/2022 - 01/2021